Dr Thomas A. Agbaedeng
BSc (Hons), PhD
NOVO NORDISK POSTDOCTORAL RESEARCH FELLOW
I completed my PhD at University of Adelaide, Australia, where I used a multimodal approach of meta-analysis and pre-clinical experimental models to characterise the arrhythmogenicity of epicardial fat. My PhD work led to multiple awards, including the Young Investigator Award (1st Prize) at the European Heart Rhythm Association Congress, Spain. I then began a postdoctoral position at The University of Adelaide in 2019. In 2020, I was awarded a Visiting Fellowship at Amsterdam UMC (Netherlands) to study proteomic phenotyping of epicardial fat in atrial fibrillation, funded by the Cardiac Society of Australia and New Zealand. In 2021, I was awarded University of Adelaide’s Emerging Leaders Grant for an in vitro study of cardiac fibrogenesis.
I started my Novo Nordisk Postdoctoral Research Fellowship with Professor Chris O’Callaghan (Nuffield Department of Medicine, NDM) and Dr Joanna Howson (NNRCO) in November 2021. The project builds on prior work on lipid-mediated genome-wide chromatin remodelling. I will use trans-omics approaches to develop a genome-wide map of the oxidized LDL-cholesterol-induced chromatin changes in coronary vascular cells. This will be integrated with GWAS information for cardiometabolic traits to identify new drug targets. These variants will be further tested and validated via focused in vitro experiments using cellular and molecular biology techniques.
Sex differences in clinical profile, management, and outcomes of patients hospitalized for atrial fibrillation in the United States.
Noubiap JJ. et al, (2022), European heart journal. Quality of care & clinical outcomes, 8, 852 - 860
Associations between adipokines and atrial fibrillation: A systematic review and meta-analysis.
Agbaedeng TA. et al, (2022), Nutrition, metabolism, and cardiovascular diseases : NMCD, 32, 853 - 862
Incidence and predictors of sudden cardiac death in arrhythmogenic right ventricular cardiomyopathy: a pooled analysis.
Agbaedeng TA. et al, (2022), Europace
Atrial fibrillation incidence, prevalence, predictors, and adverse outcomes in acute coronary syndromes: A pooled analysis of data from 8 million patients.
Noubiap JJ. et al, (2022), Journal of cardiovascular electrophysiology, 33, 414 - 422
Accelerated biological aging secondary to cardiometabolic risk factors is a predictor of cardiovascular mortality: a systematic review and meta-analysis
Emami M. et al, (2021), Canadian Journal of Cardiology